Primary Care Physician Attitudes Regarding Herpes Zoster Vaccine

Primary Care Physician Attitudes Regarding Herpes Zoster Vaccine: A National Survey Children’s Outcomes Research Program The Children’s Hospital Denver, CO Colorado Health Outcomes Program U. Colo. at Denver and HSC Aurora, CO Allison Kempe, MD, MPH

Vaccine Policy Collaborative Initiative § § § Matthew F. Daley, MD Lori A. Crane, Ph. D, MPH Brenda L. Beaty, MSPH Miriam Dickinson, Ph. D Jennifer Barrow, MSPH CDC Collaborators § § § Shannon Stokley, MSPH Rafael Harpaz, MD, MPH Mona Marin, MD § § Christine Babbel, MSPH John Steiner, MD, MPH Arthur Davidson, MD, MSPH Stephen Berman, MD

Herpes Zoster Morbidity § Herpes zoster (HZ) results from the reactivation of the varicella zoster virus § Incidence of HZ increases with age— 10 per 1, 000 persons > 75 years old § > 1 million people each year in U. S. affected § Postherpetic neuralgia (PHN): • Pain lasting > 3 months after crusting of HZ rash • Can be difficult to treat • May result in multiple office visits, subspecialty care and medications

Herpes Zoster Vaccination § Clinical trial of a vaccine against HZ reported in the Shingles Prevention Study in 2005: • Participants ≥ 60 years, Hx varicella or lived in U. S. for ≥ 30 years, not immunocompromised • ↓ of 61% in HZ burden score; ↓ of 51% in incidence • ↓ of 67% in incidence of PHN § Vaccine was licensed in 5/2006 § Provisional ACIP recommendations 10/2006 : • A single dose for adults > 60 years of age • Persons with chronic medical conditions may be vaccinated, unless contraindication or precaution *(Oxman et al. , NEJM 2005)

Study Objectives To determine in a nationally representative sample of general internists and family medicine physicians: § Perceived burden of Herpes Zoster (HZ) and Post. Herpetic Neuralgia (PHN) in primary care practice § Intentions for recommending a new HZ vaccine § Perceived barriers to HZ vaccination

Study Populations § Survey conducted in two Sentinel Provider Networks (GIM and FM) • Providers recruited from random samples of ACP and AAFP to participate in 2 -4 short surveys per year • Initial respondents post-stratified to be representative of ACP and AAFP with respect to: § § § Region of country (NE, S, MW, W) Location (urban, suburban, rural) Setting (private, managed care, community/hospitalbased) • Respondents practicing <50% primary care excluded

Final GIM and FM Sentinel Provider Networks § 438 GIM physicians eligible and selected § 433 FM physicians eligible and selected § In prior studies involving these two networks, attitudes of sentinel physicians found to be comparable to attitudes of physicians randomly sampled from the AMA

Survey Design § Survey conducted from November - December 2005 § Contained informational paragraph about the clinical trial regarding the new herpes zoster vaccine—providers asked to respond based on this information § Pilot-tested in community advisory panel composed of internists and family medicine physicians from across country

Survey Administration § Survey administered over an 8 -week period by internet or mail based on preference § Internet protocol: • Web-based survey company • Emails sent with links to internet survey • Up to 9 e-mail reminders § Mail protocol: (Dillman protocol) • A pre-letter, 3 days later an initial cover letter and survey sent • 5 days later a reminder postcard and up to 2 additional follow-up surveys

Results: Response Rates § GIM response rate - 62% (N=272) § FM response rate - 76% (N=328) § Respondent and non-respondents did not differ significantly in either group by: • Age or gender of physician • Practice type, practice location or region of the country

Characteristics of Respondents Characteristic GIM (n=270) FM (n=325) Gender (male) 65% 61% Practice Setting Private Hospital or clinic HMO/other 79% 17% 4% 79% 19% 3% Region West South Northeast Midwest 24% 27% 22% 25% 31% 15% 29% Location of practice Urban, inner-city Suburban / Urban, non-inner city Rural 12% 73% 15% 5% 60% 35%

Perception Of Burden Of Disease Caused By HZ And PHN Median # per year FM/GIM Combined (n=595) HZ cases in immunocompetent ≥ 50 y. o. 3 -4 PHN cases in immunocompetent ≥ 50 y. o. 1 -2 Median # visits to treat HZ 2 Median # visits to treat PHN 4

Perception Of Burden Of Disease Caused By HZ And PHN Combined FM / GIM (n=595) Refer to subspecialist for HZ 26% Refer to subspecialist for PHN 64% Most commonly refer HZ patients to. . Ophthalmologist Dermatologist 24% 6% Most commonly refer PHN patients to. . Pain Specialist Neurologist 40% 32%

Perceived Burden of HZ and PHN Combined FM / GIM (n=595) HZ and PHN cause significant burden of disease in my older patients Strongly agree Somewhat or strongly disagree 35% 46% 19%

The Burden Of HZ And Its Complications Warrants Vaccine GIM (n=270) p=<. 0001 Ref NS

The Burden Of HZ And Its Complications Warrants Vaccine FM (n=325) p=<. 0001 Ref NS

Comparison Of GIM And FM: Strongly Agree That Burden Of HZ And Its Complications Warrants Vaccine p=NS p=. 007 p=. 02

Likelihood Of Recommending HZ Vaccination (FM/GIM Combined; n=595)

Comparison Of GIM And FM: Very Likely To Recommend HZ Vaccination p=. 01 p=NS

Barriers to Vaccination – Ranked Highest to Lowest Barrier Combined GIM / FM (n=595) Lack of adequate reimbursement* Definitely a barrier 38% (GIM 31%, FM 44%) Somewhat a barrier 38% Not a barrier / minor barrier 24% Patients unwilling to pay if not covered by insurance Definitely a barrier 37% Somewhat a barrier 43% Not a barrier / minor barrier 19% “Up-front” costs to purchase vaccine Definitely a barrier 30% Somewhat a barrier 35% Not a barrier / minor barrier 35% *p-value =. 002

Barriers to Vaccination – Ranked Highest to Lowest Barrier Combined GIM / FM (n=595) Patients will not think they need this vaccine Definitely a barrier Somewhat a barrier Not a barrier / minor barrier 22% 45% 33% Insufficient information about duration of protection Definitely a barrier Somewhat a barrier Not a barrier / minor barrier 22% 40% 38% Insufficient information about safety Definitely a barrier Somewhat a barrier Not a barrier / minor barrier 17% 35% 48% Physician doesn’t think patients need vaccine Definitely a barrier Somewhat a barrier Not a barrier / minor barrier 14% 20% 65%

Barriers to Vaccination – Ranked Highest to Lowest Barrier Combined GIM / FM (n=595) Patients will be concerned about the safety of administering a live attenuated vaccine to patients w/ chronic medical conditions Definitely a barrier Somewhat a barrier Not a barrier / minor barrier 12% 37% 50% Degree of effectiveness of the vaccine is insufficient to warrant its use Definitely a barrier Somewhat a barrier Not a barrier / minor barrier 11% 33% 56% Physician concerns about immunosupressed household members of the patient potentially being exposed to vaccine virus Definitely a barrier Somewhat a barrier Not a barrier / minor barrier 10% 37% 52%

“Definitely A Barrier” For Less Than 10% Of Providers § Need to store HZ vaccine in a freezer rather than a refrigerator § Physician concerns about safely administering a live attenuated virus to patients with chronic medical conditions § Concern that many patients will not be eligible if the FDA does not approve the vaccine for persons excluded from the study § Fact that vaccine will not be licensed for immunosupressed patients

“Definitely A Barrier” For Less Than 10% Of Providers § Concern that many patients will be unsure of whether they have had varicella in the past § Concern that many older patients are foreignborn, have been in the U. S. less than 30 years and therefore will not be eligible to receive this vaccine § Concern that the vaccine could be mistakenly given to a child

Perceptions Associated With Reporting Being Very Likely To Recommend Herpes Zoster Vaccine To Adults 60 -79 (FM/GIM Combined; N=572) Physician perceptions Multivariate OR** (95% CI) Specialty FM vs GIM 1. 23 (0. 84 -1. 81) HZ and PHN disease cause high burden in older patients 2. 75 (1. 85 -4. 09) Insufficient information about duration of protection afforded by vaccine 0. 40 (0. 24 -0. 67) Need to store herpes zoster vaccine in a freezer 0. 31 (0. 13 -0. 75) Not thinking patients need the vaccine 0. 32 (0. 16 -0. 63) Concern that If herpes zoster is not covered by insurance, patients will be unwilling to pay out of pocket 0. 57 (0. 38 -0. 86)

Study Limitations § Potential for bias in those who respond to surveys § Measuring intention to vaccinate rather than action taken

Summary of Findings § Approximately 80% of FM and GIM providers strongly/somewhat agreed that HZ and PHN cause significant burden of disease in their older patients § The percentage of physicians strongly agreeing that burden was sufficient to warrant a vaccine was significantly higher for patients 60 -79 compared with patients 50 -59 years of age • FM 29% vs 17% • GIM 40% vs 15%

Summary of Findings § Overall, both FM and GIM providers reported being very/somewhat likely to recommend HZ vaccination for all age groups, but were significantly more likely to recommend in patients ≥ 60 than those 50 -59 years • FM 78% vs 60% • GIM 79% vs 57%

Summary of Findings § Major perceived barriers to vaccine included: • Financial - top 3 (inadequate reimbursement, up-front costs, patient unwillingness to pay) • Patients not perceiving the need • Insufficient info about duration of protection/safety

Summary of Findings § Physician characteristics and perceptions associated with being very likely to recommend included: (+) Perceiving high burden of HZ disease (-) Perceiving insufficient info about duration of protection, need to store in a freezer, and concerns about insurance coverage of vaccine

Acknowledgments This investigation was funded by the Centers for Disease Control and Prevention, through the Rocky Mountain Prevention Research Center, Denver, CO

Open-ended responses re: groups that physicians would consider for off-label use • • • (15% of pooled respondents) Overtly immunocompromised patients Functionally immunocompromised patients and those with various chronic diseases Persons with less ability to tolerate shingles Persons with varicella during infancy Persons with prior history of shingles, especially if severe Immigrants Persons that could pose risk of infection to others Healthy persons < 50 with history of varicella Healthy children and adults susceptible to varicella

Comparison of GIM and FM: Strongly/Somewhat Agree that burden of HZ and its complications in patients warrant vaccine use p=NS p=. 01

Comparison of GIM and FM: Very/Somewhat Likely to recommend HZ vaccination p=NS